

KRAS THINK TANK MEETING 2025

THE LEADING
GLOBAL FORUM
ON KRAS MUTATIONS

THURSDAY,
MAY 22
13:00 - 20:30 CET

**AUDITORI, HOSPITAL
UNIVERSITARI DEXEUS**
C/SABINO DE ARANA 5-19, BARCELONA

CHECK THE FULL PROGRAM →



FEATURING STANDOUT CONTRIBUTIONS FROM
DR. RAFAEL ROSELL AND OTHER INTERNATIONAL
LEADERS IN KRAS-MUTATED CANCER CARE.

EVENT AGENDA

ORGANIZED BY RAFAEL ROSELL - RROSELL@ONCOROSELL.COM

Hybrid meeting coordination & technical support provided
by Marc Resina: mresina@panoncology.com

The meeting will run non-stop, except for a brief 15 minute coffee/snack break at 16:15

13:00 A GLIMPSE OF KIRSTEN RAT SARCOMA VIRAL ONCOGENE

13:10 Rafael Rosell, IOR, Hospital Dexeus, Barcelona, Spain.

13:10 GFS784, A NEXT-GENERATION ADC WITH NOVEL PAN RAS(ON) PAYLOAD FOR RAS
13:35 AND EGFR MUTATED TUMOR  VIRTUAL

Siyuan Le, GenFleet Therapeutics, Shanghai, China.

13:40 RMC-6236 (PAN RAS(ON) INHIBITOR) OR TEPOTINIB (MET INHIBITOR) PLUS
13:50 OMEPRAZOLE IN KRAS-MUTATED NSCLC

Kevin Valencia, Fundación IOR, Barcelona; IGTP, Badalona, Spain.

13:50 A PROPOS OF INCREASED MUC1 EXPRESSION IN RESPONSE TO KRAS INHIBITION:
14:00 M1231 BISPECIFIC MUC1/EGFR ADC IN NSCLC

Jordi Codony-Servat, Fundación IOR, Barcelona; IGTP, Badalona, Spain.

14:00 FULZERASIB PLUS OMEPRAZOLE IN KRAS G12C NSCLC

14:15 Mengxin Zhou, Fundación IOR, Barcelona; IGTP, Badalona, Spain.

Chairpersons: Vanesa Gregorc, Eduardo Richardet  VIRTUAL

14:20 MOVING FORWARD FROM KROCUS TO PHASE III TRIALS

14:35 Vanesa Gregorc, Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Italy.
Alessandro Di Federico, IRCCS Azienda Ospedaliero Univ. Bologna, Italy.

14:40 IN VITRO ANALYSIS OF FULZERASIB AND SOTORASIB COMBINATION WITH
14:50 CETUXIMAB IN KRAS G12C NSCLC

Daniel Olmo, Fundación IOR, Barcelona, Spain.

14:50 METABOLOMIC APPROACH EVALUATING AMINO ACID ALTERATIONS IN KRAS-MUTANT NSCLC
15:10 TREATED WITH FULZERASIB OR SOTORASIB W/WITHOUT CETUXIMAB  VIRTUAL

Nuno G. Oliveira, Research Institute for Medicines, University of Lisbon, Portugal.

15:15 – 15:25 GAUGING KRAS G12C MUTANT CELL EARLY REWIRING AT THE TRANSCRIPT LEVEL AFTER FULZERASIB W/WITHOUT CETUXIMAB

Ana Giménez-Capitán, *Pangaea Oncology, Hospital Dexeus, Barcelona, Spain.*

15:30 – 15:40 NON-CANONICAL CETUXIMAB EFFECTS ON NRF2, AURKA AND SERINE SYNTHESIS PATHWAY

Mengxin Zhou, *Fundación IOR, Barcelona; IGTP, Badalona, Spain.*

15:40 – 16:10 KROCUS TRIALIST ROUNDTABLE

Alessandro Di Federico¹, Anna Koumarianou², Andrés Aguilar³, Jorge González³, Margarita Majem⁴, Yu Wang⁵, Haige Shen⁵, Jo Monsen⁶, Chiara Lazzari⁷.

¹ *IRCCS Azienda Ospedaliero-Universitaria, Bologna, Italy.*

² *University General Hospital “Attikon”, Athens, Greece.*  VIRTUAL

³ *IOR, Hospital Dexeus, Barcelona, Spain.*

⁴ *Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.*

⁵ *GenFleet Therapeutics, Shanghai, China.*  VIRTUAL

⁶ *Patient Advocate, Oslo, Norway.*

⁷ *Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Italy.*

SNACK BREAK IN OUTDOOR PATIO

The patio will remain open throughout the program. Snacks will be available from 16:15 – 17:30.

16:30 – 16:45 USING AI TO AUGMENT CANCER RESEARCH BENEFIT

Javier Castro, *AI Senior Advisor, Madrid, Spain.*

Chairpersons: Lluís Cirera, Miguel Ángel Molina-Vila

16:45 – 17:00 DIAGNOSIS AND TREATMENT OF PDAC

Ekaterina Meshoulam Nikolaeva, *IOR, Hospital Dexeus, Barcelona, Spain.*

17:05 – 17:30 KEYNOTE LECTURE: A THERAPEUTIC STRATEGY AGAINST KRAS-DRIVEN PANCREATIC DUCTAL ADENOCARCINOMA

Mariano Barbacid, *Centro Nacional de Investigaciones Oncológicas, Madrid, Spain.*

Chairpersons: José Miguel Sánchez, Alejandro Martínez Bueno

17:30 – 17:45 COMBINATORIAL STRATEGIES WITH OTHER TARGETED AGENTS  VIRTUAL

Mariacarmela Santarpia, *Messina, Italy.*

17:45	COMBINATION WITH IMMUNE CHECKPOINT INHIBITORS
18:00	Irene Moya, <i>IOR, Hospital General Cataluña, Barcelona, Spain.</i>
18:00	NEOANTIGEN BASED IMMUNOTHERAPY
18:15	María González Cao, <i>IOR, Hospital Dexeus, Barcelona, Spain.</i>
18:15	A CASE OF LUNG CANCER CRISIS: TEN-YEAR SURVIVAL OF A KRAS G12C NSCLC
18:25	PATIENT WITH LIVER AND LUNG METASTASES
	Andrés Aguilar, <i>IOR, Hospital Dexeus, Barcelona, Spain.</i>
18:25	PHASE I CLINICAL TRIALS
18:40	Tatiana Hernández, <i>MD PhD MBA, START-HM Nou Delfos, Barcelona, Spain.</i>
18:40	HARNESSING CLINICAL TRIALS: THE CRUCIALITY OF MONITORING
18:55	Andrea Arcas, <i>Carles Esparré, Data Management, IOR, Hospital Dexeus, Barcelona, Spain.</i>

Chairpersons: Miguel Ángel Molina, Rafael Rosell

19:00	XPO INHIBITION IN KRAS-MUTANT NSCLC
19:10	Jèssica González, <i>Fundación IOR, Barcelona; IGTP, Badalona, Spain.</i>
19:10	UTILITY OF NEXT-GENERATION SEQUENCING IN KRAS-MUTANT NSCLC PATIENTS
19:30	Clara Mayo, <i>Pangaea Oncology, Hospital Dexeus, Barcelona, Spain.</i>
19:30	EVOLUTION OF PLASMA mRNA LEVELS IN KRAS G12C-MUTANT NSCLC
19:40	Ana Giménez-Capitán, <i>Pangaea Oncology, Hospital Dexeus, Barcelona, Spain.</i>
19:40	RELEVANCE OF KRAS AMPLIFICATION IN CANCER
19:50	Miguel Ángel Molina, <i>Pangaea Oncology, Hospital Dexeus, Barcelona, Spain.</i>
19:50	CTCs AS A RESOURCE IN KRAS-MUTANT NSCLC  VIRTUAL
20:00	Carlos Pedraz, <i>Weill Cornell Univ, New York, USA & Pangaea Oncology, Barcelona.</i>
20:00	ONCOLOGIST’S POINT OF VIEW FROM CHAMPALIMAUD FOUNDATION  VIRTUAL
20:10	Nuno Gil, <i>Champalimaud Foundation, Lisbon, Portugal.</i>
20:10	FAREWELL REMARKS
20:15	Rafael Rosell.

INVITED GUESTS

- Siyuan Le. *GenFleet Therapeutics. Shanghai, China.*
 - Mariano Barbacid. *Centro Nacional de Investigaciones Oncológicas (CNIO). Madrid, Spain.*
 - Vanesa Gregorc. *Candiolo Cancer Institute, FPO-IRCCS. Candiolo, Italy.*
 - Chiara Lazzari. *Candiolo Cancer Institute, FPO-IRCCS. Candiolo, Italy.*
 - Eduardo Richardet. *Director of Instituto Oncológico Córdoba, Argentina.*
 - Nuno G. Oliveira. *Research Institute for Medicines, University of Lisbon, Portugal.*
 - Alessandro Di Federico. *IRCCS Azienda Ospedaliero. Univ. Bologna, Italy.*
 - Anna Koumarianou. *University General Hospital "Attikon". Athens, Greece.*
 - Jo Monsen. *Patient Advocate. Oslo, Norway.*
 - Margarita Majem. *Hospital de Santa Creu i Sant Pau, Barcelona, Spain.*
 - Yu Wang. *GenFleet Therapeutics. Shanghai, China.*
 - Haige Shen. *GenFleet Therapeutics. Shanghai, China.*
 - Javier de Castro. *AI Senior Advisor. Madrid, Spain.*
 - José Miguel Sánchez Torres. *Centro Integral Oncológico Clara Campal. Madrid, Spain.*
 - Mariacarmela Santarpia. *Dip di Patologia Umana dell'Adulto e dell'Eta Evolutiva "G.Barresi", UOC. Oncologia Medica con Hospice, AOU Policlinico "G. Martino, Messina, Italy.*
 - Tatiana Hernández. *MD PhD MBA. START-HM Nou Delfos, Barcelona, Spain.*
 - Carlos Pedraz. *Weill Cornell Univ, New York, USA & Pangaea Oncology, Barcelona.*
-
- Fundación IOR & IGTP Oncology Laboratory. *Jordi Codony-Servat, Jèssica González, Daniel Olmo, Kevin Valencia-Clua, Mengxin Zhou, Rafael Rosell.*
 - Pangaea Oncology Laboratory. *Ana Giménez-Capitán, Clara Mayo, Carlos Pedraz-Valdunciel, Beatriz García, Cristina Aguado, Cristina Rodríguez, Cristina Saucedo, Ruth Román, Jordi Bertrán-Alamillo, Nuria Jordana, Mónica Garzón, Silvia García-Román, Noelia Armiger, Susana Muñoz, María José Catalán, Sonia Rodríguez, Marta Vives, Marta García, Erika Aldeguer, Joselyn Valarezo, Malena Vez, Elba Marín, Elizabeth Martínez, Miguel Ángel Molina-Vila.*
 - IOR - Hospital Universitari Dexeus, Medical Oncology Service. *Alejandro Martínez Bueno, Andrés Aguilar, María González-Cao, Juan José García Mosquera, Ekaterina Meshoulam Nikolaeva, Jorge Christian Gonzáles, Montserrat Velasco, Víctor Albarrán, Laia Garrigós, Daniela Camacho, Clara Vidal.*
 - IOR - Hospital Sagrat Cor, Medical Oncology Service. *Lluís Cirera, Roxana Reyes.*
 - IOR - Hospital General de Catalunya, Medical Oncology Service. *Xavier González, Francesc Pons, Irene Moya, Vanesa Ortega Cebrián.*
 - IOR - Hospital Teknon, Medical Oncology Service. *Víctor Albarrán, Roxana Reyes.*
 - IOR - Data Management Team. *Carles Esparré Casal, Laura Raventós Soler, Andrea Arcas García, Alba Parra, María Cordero, Berta Costa, Marta Juan, Marina García.*

Fundación  **IOR**